Ignite Creation Date:
2024-05-06 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 12:46 PM
Study NCT ID:
NCT03542097
Status:
COMPLETED
Last Update Posted:
2023-05-15
First Post:
2018-05-17
Brief Title:
Assessment of MGMT Promoter Methylation in Advanced Ewing Sarcoma Treated With Temozolomide and Irinotecan
Sponsor:
Istituto Ortopedico Rizzoli
Organization:
Istituto Ortopedico Rizzoli
Study Overview
Official Title:
Assessment of MGMT Promoter Methylation and Clinical Benefit From Temozolomide-based Therapy in Ewing Sarcoma Patients
Status:
COMPLETED
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MGMTLiberati
Brief Summary:
This is a biological study in patients with advanced Ewing Sarcoma who received according clinical practice temozolomide and irinotecan The O6-methylguanine-DNA methyltransferase MGMT methylation status will be correlated with the disease clinical data and with the disease response
Detailed Description:
This is a biological study in patients with advanced Ewing Sarcoma who received according clinical practice temozolomide and irinotecan
The MGMT methylation status will be correlated with the disease clinical data and with the disease response also in term of metabolic activity if data will be available The MGMT methylation analysis will be performed extracting from fresh tumor sample the DNA on the basis of the standard protocols
The MGMT methylation status will be correlated with the disease clinical data and with the disease response also in term of metabolic activity if data will be available The MGMT methylation analysis will be performed extracting from fresh tumor sample the DNA on the basis of the standard protocols
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None